RBX 2660

Drug Profile

RBX 2660

Alternative Names: Microbiota restoration therapy - Rebiotix; Microbiota suspension - Rebiotix; RBX-2660

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rebiotix
  • Developer Rebiotix; University of Alberta
  • Class Antibacterials; Antidiarrhoeals; Antiulcers; Hepatoprotectants; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Clostridium infections
  • New Molecular Entity No

Highest Development Phases

  • Phase III Clostridium-difficile-infections
  • Phase I/II Hepatic encephalopathy
  • Phase I Urinary tract infections; Vancomycin-resistant enterococcal infections
  • Phase 0 Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 19 Dec 2017 McMaster Children's Hospital plans the phase I PediCRaFT trial for Crohn's disease, Inflammatory bowel disease, Ulcerative colitis (In children, In adolescents) in Canada (NCT03378167)
  • 04 Oct 2017 Efficacy data from a phase IIb PUNCH CD2 trial in Clostridium difficile infections (Recurrent) presented at the IDWeek 2017 (iDW 2017)
  • 31 Jul 2017 Phase-III clinical trials in Clostridium difficile infections (Recurrent, Prevention) in USA (Rectal) (NCT03244644)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top